101382-55-2 Usage
Description
2-Hydroxy-7-methoxy-quinoline-3-carbaldehyde is a chemical compound belonging to the quinoline family, characterized by its yellow crystalline solid appearance and solubility in organic solvents. It is defined by the molecular formula C14H11NO3 and is recognized for its applications in the synthesis of pharmaceuticals and agrochemicals, as well as its antifungal and antibacterial properties, positioning it as a significant compound in medicinal chemistry.
Uses
Used in Pharmaceutical Industry:
2-Hydroxy-7-methoxy-quinoline-3-carbaldehyde serves as a key intermediate in the synthesis of various pharmaceuticals, contributing to the development of new drugs and therapeutic agents. Its chemical structure allows for the creation of molecules with potential medicinal properties, enhancing the range of treatments available for different health conditions.
Used in Agrochemical Industry:
In the agrochemical sector, 2-Hydroxy-7-methoxy-quinoline-3-carbaldehyde is utilized as a precursor in the production of agrochemicals, specifically those with antifungal and antibacterial properties. This application helps in the development of effective solutions for crop protection and management of plant diseases, thereby supporting agricultural productivity.
Used in Medicinal Chemistry Research:
2-Hydroxy-7-methoxy-quinoline-3-carbaldehyde is employed as a valuable chemical in medicinal chemistry research, where its antifungal and antibacterial properties are explored for potential applications in the treatment of various infections and diseases. Its unique structure and properties make it a promising candidate for the development of novel antimicrobial agents.
Check Digit Verification of cas no
The CAS Registry Mumber 101382-55-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,0,1,3,8 and 2 respectively; the second part has 2 digits, 5 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 101382-55:
(8*1)+(7*0)+(6*1)+(5*3)+(4*8)+(3*2)+(2*5)+(1*5)=82
82 % 10 = 2
So 101382-55-2 is a valid CAS Registry Number.
InChI:InChI=1/C11H9NO3/c1-15-9-3-2-7-4-8(6-13)11(14)12-10(7)5-9/h2-6H,1H3,(H,12,14)
101382-55-2Relevant articles and documents
Design and Evaluation of Quinolone Derivatives as Potent Inhibitors of Wild-type TTR and V30M TTR Amyloidogenesis
Jung, Jiman,Lee, Namgeol,Park, Hwanggue,Park, Sung Jean,Choi, Sungwook
, p. 719 - 722 (2015)
-
Cysteine driven decomposition and quenching of a fluorescent metalloreceptor: Optical detection and mechanistic insight
Asthana, Sharad Kumar,Kumar, Ajit
, (2022/01/13)
We herein devised a fluorescent metalloreceptor (ZNQ) for selective recognition of cysteine (Cys) via fluorescence suppression. The metalloreceptor, ZNQ is a Zn2+ complex of Quinolineimines based ligand (CMO). The surgical action of Cys over metalloreceptor (ZNQ) finishes in three steps viz. demetallation, hydrolysis of schiff base (CMO) i.e. ligand itself and finally cyclization of aldehyde. Interestingly this type of synergistic mechanistic approach have never been reported in the literature for the detection of any thiols. The structure of metalloreceptor ZNQ was confirmed by single crystal X-ray diffraction and its interaction with Cys have been explored through various spectroscopic studies. The bioimaging of Zn2+ and Cys were also carried out in the living HeLa cell.
BICYCLIC HETEROCYCLIC DERIVATIVES AS BROMODOMAIN INHIBITORS
-
, (2017/04/04)
The present disclosure provides bicyclic heterocyclic derivatives of formula (I), which may be therapeutically useful, more particularly as bromodomain inhibitors; (I), in which R1, R2, R3, R4, L1, L2, Cy1, Cy2, X, n, and dotted line have the same meaning given in the specification, and pharmaceutically acceptable salts or pharmaceutically acceptable stereoisomers thereof that are useful in the treatment and prevention of diseases or disorders, in particular their use in diseases or disorders associated as bromodomain inhibitors. The present disclosure also provides preparation of compounds and pharmaceutical formulations comprising at least one of bicyclic heterocyclic derivatives of formula (I), together with a pharmaceutically acceptable carrier, diluent, or excipient.
